EGFR and head and neck squamous cell carcinoma: Concurrent inhibition of EGFR (by gefitinib) and HGF/c-MET (via crizotinib or SU11274) significantly affected HNSCC cell line proliferation, invasion, and wound healing compared to individual inhibitors.